secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRYO CELL INTERNATIONAL INC (CCEL)
CIK:        0000862692
Form:       8-K
Filed at:   2021-10-15T23:59:59+00:00
Accession:  0001564590-21-050957
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryo-Cell Q3 2021 revenue down 8% to $7.5M; net income $857K
------------------------------------------------------------

- Revenue $7.5M vs $8.1M YoY; processing/storage fees $7.3M, public banking $159K.
- Net income $857K ($0.10 per share) vs $784K ($0.10) in Q3 2020.
- Cost of sales +4%, SG&A +3% due to $167K for Cellular Therapies Institute and $131K Duke patent license expenses.
- Recorded $325K decrease in fair value of contingent consideration liability for Cord:Use earn-out.
- No guidance provided; company highlights transformation into cellular therapy company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/862692/000156459021050957/0001564590-21-050957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/862692/000156459021050957/ccel-8k_20211015.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-050957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer